Research programme: in-vivo CRISPR editing gene therapies - Orna Therapeutics
Latest Information Update: 24 Oct 2024
At a glance
- Originator Orna Therapeutics
- Class Antianaemics; Gene therapies; RNA
- Mechanism of Action Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Beta-thalassaemia; Sickle cell anaemia
Most Recent Events
- 22 Oct 2024 Preclinical trials in Beta-thalassaemia in USA (Parenteral) before October 2024
- 22 Oct 2024 Preclinical trials in Sickle cell anaemia in USA (Parenteral) before October 2024
- 22 Oct 2024 Pharmacodynamics data from preclinical studies in Sickle cell anaemia and Beta thalassaemia released by Orna Therapeutics